New 'In Vivo' CAR-T therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07322159
Summary
This is a very early study to check the safety and first signs of effectiveness of a new type of CAR-T therapy called IASO206 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The therapy is designed to be given directly into the body (in vivo) to reprogram the patient's own immune cells to attack the cancer. The study will enroll 12 patients to closely monitor for side effects and see if the treatment can reduce the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.